phenyl 3,4-di-O-acetyl-2-O-benzyl-6-deoxy-1-thio-β-D-allopyranoside | 868258-61-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: phenyl 3,4-di-O-acetyl-2-O-benzyl-6-deoxy-1-thio-β-D-allopyranoside
• 英文别名: [(2R,3R,4R,5R,6S)-4-acetyloxy-2-methyl-5-phenylmethoxy-6-phenylsulfanyloxan-3-yl] acetate
• CAS: 868258-61-1
• 化学式: C₂₃H₂₆O₆S
• 分子量: 430.522
• InChiKey: OESKCJVZEVEFLO-XTSSOZKMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  96.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  phenyl 3,4-di-O-acetyl-2-O-benzyl-6-deoxy-1-thio-β-D-allopyranoside 在 4-二甲氨基吡啶 、 sodium methylate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 Benzoic acid (2R,3R,4R,5R,6S)-5-benzyloxy-2-methyl-6-phenylsulfanyl-4-trifluoromethanesulfonyloxy-tetrahydro-pyran-3-yl ester
  参考文献：
  名称：

  Glycodiversification for the Optimization of the Kanamycin Class Aminoglycosides

  摘要：

  In an effort to optimize the antibacterial activity of kanamycin class aminoglycoside antibiotics, we have accomplished the synthesis and antibacterial assay of new kanamycin B analogues. A rationale-based glycodiversification strategy was employed. The activity of the lead is comparable to that of commercially available kanamycin. These new members, however, were found to be inactive against aminoglycoside resistant bacteria. Molecular modeling was used to provide the explanation. Thus, a new strategy for structural modifications of kanamycin class aminoglycosides is suggested.

  DOI：

  10.1021/jm050368c
• 作为产物：
  描述：

  phenyl 2-O-benzyl-1-thio-β-D-fucopyranoside 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 phenyl 3,4-di-O-acetyl-2-O-benzyl-6-deoxy-1-thio-β-D-allopyranoside
  参考文献：
  名称：

  Glycodiversification for the Optimization of the Kanamycin Class Aminoglycosides

  摘要：

  In an effort to optimize the antibacterial activity of kanamycin class aminoglycoside antibiotics, we have accomplished the synthesis and antibacterial assay of new kanamycin B analogues. A rationale-based glycodiversification strategy was employed. The activity of the lead is comparable to that of commercially available kanamycin. These new members, however, were found to be inactive against aminoglycoside resistant bacteria. Molecular modeling was used to provide the explanation. Thus, a new strategy for structural modifications of kanamycin class aminoglycosides is suggested.

  DOI：

  10.1021/jm050368c